Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 11:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 404 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Skin Diseases Clear all
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07213973
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT07049575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Fountain Valley, California • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Not applicable Interventional

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

NCT01063270
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
Drug · Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00107978
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 19, 2026, 11:04 AM EDT
Completed No phase listed Observational

Wound Etiology and Healing Study

NCT01352078
View directory record Official record
Conditions
Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 19, 2026, 11:04 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

BIO-SEE: Bioburden Imaging Outcome Study for Equivalence Evaluation

NCT07611318
View directory record Official record
Conditions
DFU, VLU, Surgical Wound, Wounds, Pressure Injuries
Interventions
cureVision cV
Diagnostic Test
Lead sponsor
Capsicure, LLC
Network
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
5
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

NCT00750152
View directory record Official record
Conditions
Tinea Cruris, Jock Itch
Interventions
NAFT-500, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effect of Jublia on Dermatophytomas

NCT03098615
View directory record Official record
Conditions
Onychomycosis, Dermatophytosis
Interventions
Jublia (Efinaconazole 10% Topical Solution)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

NCT01014962
View directory record Official record
Conditions
Onychomycosis
Interventions
Albaconozole, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

NCT00555061
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Ointment, 1%
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Months to 24 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Tuscaloosa, Alabama • Bentonville, Arkansas • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 2 Interventional Results available

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

NCT00758862
View directory record Official record
Conditions
Secondarily Infected Traumatic Lesions (SITL), Impetigo
Interventions
2% TD1414 Cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 19, 2026, 11:04 AM EDT
Recruiting Not applicable Interventional

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

NCT07316192
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Pelashield Painguard
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Not applicable Interventional Results available

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

NCT00261807
View directory record Official record
Conditions
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
Interventions
Daptomycin 6mg/kg/day
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 19, 2026, 11:04 AM EDT
Not listed Not applicable Interventional

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

NCT02759900
View directory record Official record
Conditions
Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts
Interventions
Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 19, 2026, 11:04 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Spread of Dermatophytes Among Families

NCT00233493
View directory record Official record
Conditions
Onychomycosis, Tinea Pedis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
14 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 ( naftin 2 % gel ), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 19, 2026, 11:04 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

NCT07155239
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
AviClear Lase Treatment, Sham (No Treatment)
Device
Lead sponsor
Wynn Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rosemead, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 19, 2026, 11:04 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
12 Years and older
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
49
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Not applicable Interventional

Aviclear for Hidradenitis Suppurativa (HS)

NCT06801795
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
AviClear
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 19, 2026, 11:04 AM EDT
Terminated Not applicable Interventional

Hidradenitis Suppurativa Written Action Plan

NCT04230291
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Verbal consultation, Written Action Plan
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Sep 19, 2026, 11:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care

NCT05226260
View directory record Official record
Conditions
Cellulitis, Abscess, Drain Abscess, Impetigo, Skin Infection, Antibiotic Duration, Behavioral Economics
Interventions
Default Duration order Panel
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Months to 99 Years
Enrollment
1,634 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 19, 2026, 11:04 AM EDT